Dompé receives orphan drug designation for investigational ophthalmic treatment

December 4th, 2015 | Posted by admin in Uncategorized

The Dompé biopharmaceutical company has announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth...
Source: Medical News Today

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *